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Introduction: Type 1 long QT syndrome (LQT1) is a common type of cardiac channelopathy associated with
loss-of-function mutations of KCNQ1. Currently there is a lack of drugs that target the defected slowly activating
delayed rectifier potassium channel (IKs). With LQT1 patient-specific human induced pluripotent stem cell (hiPSC)-
derived cardiomyocytes (hiPSC-CMs), we tested the effects of a selective IKs activator ML277 on reversing the
disease phenotypes.
Methods: A LQT1 family with a novel heterozygous exon 7 deletion in the KCNQ1 gene was identified.
Dermal fibroblasts from the proband and her healthy father were reprogrammed to hiPSCs and subsequently
differentiated into hiPSC-CMs.
Results: Compared with the control, LQT1 patient hiPSC-CMs showed reduced levels of wild type KCNQ1 mRNA
accompanied by multiple exon skipping mRNAs and a ~50% reduction of the full length Kv7.1 protein. Patient
hiPSC-CMs showed reduced IKs current (tail current density at 30 mV: 0.33 ± 0.02 vs. 0.92 ± 0.21, P < 0.05) and
prolonged action potential duration (APD) (APD 50 and APD90: 603.9 ± 39.2 vs. 319.3 ± 13.8 ms, P < 0.005; and
671.0 ± 41.1 vs. 372.9 ± 14.2 ms, P < 0.005). ML277, a small molecule recently identified to selectively activate KV7.1,
reversed the decreased IKs and partially restored APDs in patient hiPSC-CMs.
Conclusions: From a LQT1 patient carrying a novel heterozygous exon7 deletion mutation of KCNQ1, we generated
hiPSC-CMs that faithfully recapitulated the LQT1 phenotypes that are likely associated with haploinsufficiency and trafficking
defect of KCNQ1/Kv7.1. The small molecule ML277 restored IKs function in hiPSC-CMs and could have therapeutic value for
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Long QT syndrome (LQTS) are inherited arrhythmic heart
diseases characterized by prolonged QT intervals on elec-
trocardiograms (ECGs) and sudden cardiac deaths. To date,
the understanding of mutation-dependent disease mecha-
nisms and the development of evidence-based clinical ther-
apies for LQTS have been hampered by a lack of ideal
disease models that enable precise analysis of disease char-
acteristics. The recent breakthrough in generating human
induced pluripotent stem cells (hiPSCs) from postnatal
humans and their ability to be differentiated into functional
cardiomyocytes (hiPSC-CMs) have opened a new page in
the study of inherited cardiac diseases such as LQTS. To
date, patient-specific hiPSC lines have been successfully
generated from individuals with types 1, 2, 3 and 8 (Timothy
syndrome) LQTS and cardiomyocytes derived from these
lines, as in vitro models, have faithfully recapitulated
cardinal cellular disease phenotypes [1-4].
Type 1 long QT syndrome (LQT1) is the most common
subtype of LQTS (~40% of all LQTS) that is associated
with loss of function of the slowly activating delayed recti-
fier potassium channel (IKs) in cardiomyocytes [5-7]. The
IKs current is mediated by the voltage-gated potassium
channel Kv7.1, which consists of the α-subunit (encoded by
KCNQ1) that forms heterodimers with β-subunits (MinK,
encoded by KCNE1). The actual ion channel is made up of
four α-subunits. The exon 6 to exon 7 junction of KCNQ1Figure 1 Data for the type 1 long QT syndrome family. (A) Family ped
patient represents prolonged QT intervals. (C) Cartoon showing the positio
QT syndrome; QTc, corrected QT interval.represents a splicing mutation hotspot and contains several
splicing mutations [8-11].
Using patient-specific hiPSC-CMs as a disease model, this
study aimed to characterize the impacts of a novel KCNQ1
mutation (heterozygous deletion of exon 7) identified in a
LQT1 patient and to evaluate the therapeutic potential of
ML277 in LQT1 hiPSC-CMs.Materials and methods
For detailed procedures, please refer to Methods in
Additional file 1.Patient recruitment
The study was approved by the SingHealth institutional
review board (Singapore) following principles in the
Declaration of Helsinki. Clinical data as well as blood and
skin samples were taken following written informed
consent. A family of LQT1 was identified based on the
clinical symptoms and ECG (Figure 1). The proband (the
LQT1 patient) and her clinically normal father (the family
control) (Figure 1A) participated in this study. The ECG
of the LQT1 patient (Figure 1B) showed typical prolonga-
tion of QT interval (corrected QT interval = 545 ms)
(Figure 1B). The ECG recorded from the father (not
shown) was normal (corrected QT interval = 398 ms).igree. (B) Electrocardiogram (ECG) of the type 1 long QT syndrome
n of exon 7-encoded pore region in the α-subunit of KV7.1. LQTS, long
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pluripotent stem cells
Dermal fibroblasts of the patient and the control were estab-
lished from the dermis tissue obtained from a 5 mm punch
skin biopsy. Fibroblasts were reprogrammed to hiPSCs via
retroviral transduction of Yamanaka transcription factors
OCT-4, SOX2, KLF4 and c-MYC [12,13]. The pluripotency
of hiPSCs was confirmed by their expression of pluripotent
stem cell markers determined by immunofluorescence assay
and further validated by teratoma formation assay. More-
over, karyotyping was performed to check the genomic
stability of hiPSCs.
Cardiac differentiation of human induced pluripotent
stem cells
Cardiac differentiation of hiPSCs was achieved via Wnt
signaling inhibition of a monolayer of hiPSCs formed from
single cells [14].
iCell Cardiomyocyte
iCell Cardiomyocyte from Cellular Dynamics International
Inc. (Madison, WI, USA), hereby called iCell, is a normal
hiPSC-CM line [15] adopted in this study as an additional
control for evaluating the effects of the ML277.
Gene expression of KCNQ1
Total RNA was isolated from hiPSC-CMs and reverse
transcribed into cDNA with Superscript III Reverse
Transcriptase (Invitrogen, Singapore, Singapore). The
expression of the KCNQ1 gene in hiPSC-CMs was mea-
sured by semi-quantitative RT-PCR assay. The PCR
products covering exon 6 to exon 9 of the KCNQ1 gene
(primers shown in Table S1 in Additional file 1) were
gel-purified and sequenced.
Total levels of Kv7.1 and its intracellular localization
The total cellular KV7.1 level was determined by western
blot. Cell lysate was prepared from the clusters of hiPSC-
CMs and incubated with primary antibody Anti-KV7.1.
The intracellular localization of KV7.1 in hiPSC-CMs was
determined by immunofluorescence assay with primary
antibodies including anti-KV7.1, anti-α-actinin and anti-
Golgi. The fluorescent intensity was quantified with
ImageJ software (National Institutes of Health, Bethesda,
MD, USA), where signals with a distance to the nucleus
less than one-half of the radius were marked as peri-
nuclear and the rest marked as membranous.
Whole cell patch-clamp recordings
Dissociated hiPSC-CMs 4 to 5 weeks post cardiac differ-
entiation were plated into 3.5 cm Petri dishes coated
with gelatin (0.1%, w/v). Whole cell patch-clamp record-
ings were conducted with an Axon patch 200B amplifier
controlled by Axon Instruments pClamp10 software viathe Digidata 1440 acquisition system software (Molecu-
lar Devices, LLC., Sunnyvale, CA, USA). Cardiac action
potentials (APs) were recorded with current-clamp proto-
cols of standard whole cell patch-clamp techniques [4]. The
IKs currents were recorded with voltage-clamp protocols of
standard whole cell patch-clamp techniques [16].
ML277, or (R)-N-(4-(4-methoxyphenyl)thiazol-2-yl)-1-
tosylpiperidine-2-carboxamide, was purchased from
Sigma-Aldrich Corp. (St Louis, MO, USA).
Statistical analyses
Numerical data are presented as the mean ± standard devi-
ation, except for the electrophysiological data that are pre-
sented as mean ± standard error of the mean. Comparisons
were performed with an unpaired Student t test (two-tailed)
and one-way analysis of variance followed by Tukey’s post
test. Pearson’s chi-squared test was used to compare the
proportions of wild type (WT) and various exon-skipping
mRNAs. P <0.05 was considered statistically significant.
Results
A novel KCNQ1 mutation was identified in the LQT1
family
An in-frame heterozygous deletion of exon 7 (C.922 ~
1,032 del; P.308 ~ 344 del) in the KCNQ1 gene, which was
not previously reported in LQT1, was identified in the pro-
band and her mother and sisters (Figure 1A). Exon 7 en-
codes a major part of the S6 transmembrane-spanning
segments (the pole region) and the loop connecting S5 and
S6 (Figure 1C). No pathogenic mutations of up to 50 other
cardiac genes (including KCNE1) responsible for inherited
heart diseases were identified.
LQT1 patient-specific hiPSCs and hiPSC-CMs were
generated
LQT1 patient and control hiPSCs were derived and their
pluripotency was confirmed in vitro and in vivo by the
expressions of typical pluripotent stem cell markers (Figure
S1A in Additional file 1) and formation of teratoma (Figure
S1B in Additional file 1), respectively. The hiPSCs main-
tained a normal karyotype (Figure S1C in Additional file 1).
LQT1 patient-specific hiPSC-CMs express reduced WT
KCNQ1 accompanied by alternative transcriptions
skipping exon 7 and exon 7 plus exon 8
hiPSCs were differentiated into hiPSC-CMs. By sequencing
of the PCR products, alternative transcriptions of KCNQ1
in LQT1 patient hiPSC-CMs were confirmed. Compared
with the control, LQT1 patient hiPSC-CMs showed a
markedly reduced expression level of the WT KCNQ1
gene, which was accompanied by a de novo alternative tran-
scription isoform skipping exon 7 (Δexon7) (Figure 2). In
addition, a significant increment of an exon 7 plus exon 8
skipping (Δexon 7 + 8) transcription was detected in patient
Figure 2 Expression of the KCNQ1 gene in LQT1 patient-derived human induced pluripotent stem cell cardiomyocytes. (A) (Left) RT-PCR images
covering KCNQ1 cDNA from exon 6 to exon 9 in control and patient human induced pluripotent stem cell cardiomyocytes (hiPSC-CMs). Blue dashed line
separates the PCR products of Δexon8 (above) from Δexon7 (below). (Right) Sequences of the corresponding PCR products. (B) Quantitative profiling of
the wild type (WT) and exon-skipping mRNAs in control and patient hiPSC-CMs. Data presented as mean ± standard deviation. **P <0.01, ***P <0.001,
versus control. bp, base pairs; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; LQT1, type 1 long QT syndrome.
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small amount of Δexon8 alone and Δexon7 + exon8 iso-
forms was detectable (Figure 2).
Our data indicate that the heterozygous Δexon 7 in
KCNQ1 led to decreased WT KCNQ1 transcription, a de
novo Δexon 7 isoform and a significant increment of the
Δexon7 + exon8 isoform.LQT1 patient-specific hiPSC-CMs expressed reduced levels
of WT Kv7.1 protein
A significant reduction of the total cellular level of the full
length (WT) α-subunit of Kv7.1 potassium channel
(~75 kDa) was observed in LQT1 patient-derived hiPSC-
CMs compared with the control. The ratios of the full
length Kv7.1 normalized to β-actin in the control and pa-
tient hiPSC-CMs (mean ± standard deviation) were 54 ±
9% and 33 ± 4% (P <0.01). However, the protein isoforms
predicted based on exon skipping in the α-subunit of
Kv7.1 were largely not detectable (Figure 3A).The immunofluorescence staining of Kv7.1 showed a peri-
nuclear localization pattern in patient hiPSC-CMs compared
with a perimembrane distribution pattern in the control
(Figure 3B). The membrane and perinuclear staining of
Kv7.1 in patient versus control was 38.6% and 61.4% versus
69.4% and 30.6% (P <0.001).
Taken together these data indicate possible haploinsuf-
ficiency and trafficking defect of KCNQ1/Kv7.1 in pa-
tient cardiomyocytes.
LQT1 patient-specific hiPSC-CMs demonstrated decreased
IKs and prolonged action potential duration
Compared with the control, the hiPSC-CMs from the LQT1
patient demonstrated decreased IKs current (Figure 4A).
The baseline level of IKs in patient hiPSC-CMs was signifi-
cantly lower than that of the family control (Figure 4A). A
positively shifted half-maximal activation voltage (V(1/2)) of
IKs activation in patient hiPSC-CMs was noted compared
with the control (Figure 5A), indicating a decreased activa-
tion of IKs. Moreover, prolonged action potential duration
Figure 3 Total levels and intracellular distributions of KV7.1 in LQT1 patient-derived human induced pluripotent stem cell cardiomyocytes.
(A) Representative western blot image of Kv7.1 (left) and bar graft showing the levels of KV7.1 plotted against β-actin (right). **P <0.01, versus control.
(B) Representative images of co-immunofluorescence staining of α-actinin (red) and KV7.1 (green) (left top panel, 63×; scale bar: 20 μM) and Golgi apparatus
(red) and Kv7.1 (green) (left middle panel, 63×; scale bar: 20 μM; and left bottom panel, 40×; scale bar: 40 μM) in control and patient human induced
pluripotent stem cell cardiomyocytes (hiPSC-CMs). Cell nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI; blue). The membranous and
perinuclear distributions of KV7.1 were quantified in KV7.1 and Golgi apparatus co-staining images by ImageJ software (National Institutes of Health,
Bethesda, MD, USA). The relative ratio was plotted and presented in a bar graph (right). **P <0.01, versus control. LQT1, type 1 long QT syndrome.
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ventricular-like subtype as the APD at 50% repolarization
and the APD at 90% repolarization in patient hiPSC-CMs
were ~1.85-fold that of the control (Figure 6A, Table 1).
Our data show that patient-specific hiPSC-CMs have
decreased amplitude and activation of IKs and shortened
APDs, indicating that patient hiPSC-CMs faithfully reca-
pitulated the typical cellular electrophysiological charac-
teristics of LQT1.
Determined by the AP properties, it is noted that a
majority (~70%) of the hiPSC-CMs from the LQT1 patient
and control were ventricular-like while the rest were atrial-
like or nodal-like hiPSC-CMs (Figure 6A, Table S2 in
Additional file 1). All subtypes of hiPSC-CMs were capableof spontaneous contraction with a lower maximal diastolic
potential. The ratio of the hiPSC-CM subtypes and the AP
properties we observed are in close agreement with pre-
vious reports [1-4,17].
KCNQ1 overexpression in LQT1 patient hiPSC-CMs rescued
the LQT1 phenotypes
Increased IKs current and shortened APD were observed
in LQT1 patient hiPSC-CMs transfected with WT human
KCNQ1 (Figure S2 in Additional file 1). It was noted that
the LQT1 phenotypes were not fully restored. This is prob-
ably because some of the green fluorescent protein-positive
cells (cells were co-transfected with a green fluorescent pro-
tein vector) selected for patch-clamp assay may not contain
Figure 4 Slowly activating delayed rectifier potassium channel measured in human induced pluripotent stem cell cardiomyocytes.
(A) Slowly activating delayed rectifier potassium channel (IKs) currents recorded in patient and control human induced pluripotent stem cell cardiomyocytes
(hiPSC-CMs). IKs currents were validated as Chromanol 293B-sensitive IKs currents (after subtraction). Averaged peak and tail current density (pA/pF) in patient
and control hiPSC-CMs (right). Values are mean± standard error of the mean (SEM; n= 7 for patient and control). *P <0.05, versus control. (B) IKs measured in
iCell Cardiomyocyte (Cellular Dynamics International Inc., Madison, WI, USA), family control and patient hiPSC-CMs treated with ML277 (left). Averaged
tail current density (pA/pF) of iCell, family control and patient hiPSC-CMs (right). Values are mean ± SEM. *P <0.05, versus baseline. LQT1, type 1 long
QT syndrome.
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the KCNQ1 mutation in our patient is responsible for the
LQT1 phenotypes.
ML277 rescued the abnormal electrophysiological
phenotypes of LQT1 in patient-specific hiPSC-CMs
To preciously evaluate the effect of ML277, iCell – the nor-
mal control hiPSC-CM adopted by Yu and colleagues for
assessing the effects of ML277 [16] – was included in thisstudy as reference. Application of ML277 to iCell, the fam-
ily control hiPSC-CMs and the LQT1 patient-specific
hiPSC-CMs uniformly led to a significant elevation of IKs
and the average IKs increments (at different voltages) were
~1.64-fold, 1.30-fold and 1.63-fold, respectively (Figure 4B).
Moreover, a negatively shifted V(1/2) of IKs, activation was
observed in both family control and patient hiPSC-CMs
treated with ML277 (Figure 5B, C), indicating that ML277
could enhance the voltage-gated activation of IKs. In
Figure 5 Activation kinetics of slowly activating delayed rectifier potassium channel measured in human induced pluripotent stem cell
cardiomyocytes. (A) Activation kinetics of slowly activating delayed rectifier potassium channel (IKs) measured in control and patient human induced
pluripotent stem cell cardiomyocytes (hiPSC-CMs). (B) Activation of IKs measured in family control hiPSC-CMs prior to and post ML277 treatment. (C)
Activation of IKs measured in patient hiPSC-CMs prior to and post ML277 treatment. The half-maximal activation voltage (V(1/2)) was calculated and
presented in the inserted tables. *P <0.05, versus control or baseline. LQT1, type 1 long QT syndrome.
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ML277 treatment shortened the APD (~20% reduction in
APD at 50% repolarization and the APD at 90% repolariza-
tion) in all types of cells (Figure 6B, Table 2). Finally, the
effect of ML277 was further validated by suppressing the
effects of ML277 with Chromanol 293B (a specific IKs
blocker) in iCell, family control and LQT1 patient hiPSC-
CMs (Figure 7). Chromanol 293B abolished ML277-
induced increased IKs and shortened the APD.
Our data indicate that ML277 is capable of reversing the
electrophysiological phenotypes in LQT1 hiPSC-CMs by in-
creasing the amplitude and enhancing the activation of IKs
and shortening APDs. Yet the effects of ML277 were not
limited to LQT1 patient hiPSC-CMs, which have compro-
mised activating IKs currents, but also extended to normalhiPSC-CMs. However, it is noted that in both patient and
control hiPSC-CMs treated with ML277, the changes in
APDs were less closely correlated with the changes in IKs.Discussion
Our data provided sufficient evidence to support that
the heterozygous deletion of exon 7 of KCNQ1 in our
LQT1 patient is pathogenic and contributes to the
LQT1 phenotypes. Our patient hiPSC-CMs recapitulated
the typical cellular electrophysiological phenotypes of
LQT1 including reduced IKs current amplitudes and ac-
tivation and prolonged APDs similar to those previously
observed in the hiPSC-CMs derived from a LQT1 pa-
tient with a missense mutation (R190Q) [2].
Figure 6 Action potential properties of human induced pluripotent stem cell cardiomyocytes. (A) Traces of spontaneous action potentials
measured in ventricular-like, atrial-like, and nodal-like human induced pluripotent stem cell cardiomyocytes (hiPSC-CMs) derived from control
and patient human induced pluripotent stem cells (hiPSCs; upper panel). Traces of paced (1 Hz) action potentials measured in ventricular-like,
atrial-like, and nodal-like hiPSC-CMs derived from control and patient hiPSCs (lower panel). (B) Traces of spontaneous (upper panel) and paced
(1 Hz) (lower panel) action potentials measured in iCell Cardiomyocyte (Cellular Dynamics International Inc., Madison, WI, USA), family control and
patient ventricular-like hiPSC-CMs at baseline (solid lines) and post ML277 treatment (dashed lines). Horizontal dashed lines crossing the AP traces
indicate a voltage of 0 mV. LQT1, type 1 long QT syndrome; SP, spontaneous.
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transmembrane-spanning segments (the pole region) and
the loop connecting S5 and S6. In LQT1 patient hiPSC-
CMs, we found that the WT α-subunit of Kv7.1 is the pre-
dominant form, suggesting that the heterozygous deletion of
exon 7 leads to haploinsufficiency associated with reduced
IKs currents and shortened APDs. On the other hand, we
found that Δexon7 in the KCNQ1 gene leads to three exon-
skipping mRNAs all known to be capable of synthesis of
truncated KV7.1 in COS7 lines, as demonstrated by Tsuji
and colleagues who identified the same panel of exon-
skipping KCNQ1 mRNAs (Δexon 7, Δexon 8 and Δexon
7 + 8) in the blood cells of a LQT1 patient withTable 1 Action potential parameters of ventricular-like huma
AP APA (mV) APD50 (ms) APD90 (ms) APD9
Spontaneous
LQT1 patient (n = 41) 98.2 ± 1.3 603.9 ± 39.2*** 671.0 ± 41.1*** 1.12 ±
Control (n = 17) 99.1 ± 2.6 319.3 ± 13.8 372.9 ± 14.2 1.18 ±
Paced (1 Hz)
LQT1 patient (n = 30) 100.4 ± 1.1 477.1 ± 23.9*** 545.3 ± 26.6*** 1.15 ±
Control (n = 8) 101.5 ± 6.5 349.9 ± 23.7 397.5 ± 32.2 1.13 ±
AP, action potential; APA, action potential amplitude; APD50, action potential durat
repolarization; LQT1, type 1 long QT syndrome; MDP, maximum diastolic potential.heterozygous splice-site missense mutation in the last base
of exon 7 (c.1032G >A) [18]. Similar to our study, Tsuji et al
noted that normal individuals had minor fractions of spli-
cing variants (Δexon 7 + 8, 0.1% of total KCNQ1 transcripts;
and Δexon 8, 6.9% of total KCNQ1 transcripts) while the
LQT1 patient had a remarkable increases of exon-
skipping mRNAs (Δexon 7, 23.5%; Δexon 7 + 8, 16.8%;
Δexon 8, 4.5%). Moreover, Tsuji and colleagues observed a
membranous distribution pattern of the wild type Kv7.1
and a perinuclear localization pattern of the truncated
proteins. However, they reported that all truncated Kv7.1
displayed no time-dependent IKs currents in Xenopus
oocytes, indicating that those truncated proteins do notn induced pluripotent stem cell cardiomyocytes
0/APD50 Overshoot (mV) MDP (mV) Heart rate (beats/minute)
0.01 40.8 ± 1.0 −58.7 ± 1.1 69.4 ± 4.7
0.02 40.0 ± 1.4 −59.8 ± 0.7 71.0 ± 5.2
0.02 42.2 ± 1.0 −58.3 ± 1.3 60
0.02 42.4 ± 2.5 −58.3 ± 3.2 60
ion at 50% repolarization; APD90, action potential duration at 90%
***P <0.005, versus control.
Table 2 Action potential parameters of ventricular-like human induced pluripotent stem cell cardiomyocytes treated with ML277
Spontaneous APs APA (mV) APD50 (ms) APD90 (ms) APD90/APD50 Overshoot (mV) MDP (mV) Heart rate (beats/minute)
LQT1 patient Baseline (n = 11) 98.4 ± 1.7 601.1 ± 51.1 665.4 ± 51.9 1.12 ± 0.01 40.1 ± 2.4 −60.9 ± 1.6 64.6 ± 6.0
ML277 (1 μM) (n = 11) 98.1 ± 1.3 455.5 ± 44.6** 514.7 ± 46.0** 1.15 ± 0.02 38.0 ± 2.8 −61.1 ± 1.7 66.9 ± 1.6
Control (father) Baseline (n = 9) 99.1 ± 3.5 315.1 ± 23.1 368.8 ± 22.5 1.13 ± 0.01 41.5 ± 1.1 −59.4 ± 1.1 75.8 ± 6.8
ML277 (1 μM) (n = 9) 99.2 ± 2.4 228.0 ± 24.4** 288.4 ± 27.4** 1.17 ± 0.02 40.7 ± 2.7 −60.6 ± 1.5 76.0 ± 8.0
AP, action potential; APA, action potential amplitude; APD50, action potential duration at 50% repolarization; APD90, action potential duration at 90% repolarization; LQT1, type 1 long QT syndrome; MDP, maximum













Figure 7 (See legend on next page.)
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Figure 7 Effects of Chromanol 293B on slowly activating delayed rectifier potassium channel and APD in ML277 treated human induced
pluripotent stem cell cardiomyocytes. (A) Effects of Chromanol 293B on slowly activating delayed rectifier potassium channel in ML277-treated iCell
Cardiomyocyte (Cellular Dynamics International Inc., Madison, WI, USA), family control and LQT1 human induced pluripotent stem cell cardiomyocytes
(hiPSC-CMs). (B) Effects of Chromanol 293B on action potential duration in ML277-treated iCell, family control and LQT1 hiPSC-CMs. *P <0.05, versus
control; ^P <0.05, versus ML277 treated. APD50, action potential duration at 50% repolarization; APD90, action potential duration at 90% repolarization;
LQT1, type 1 long QT syndrome; pA/pF, averaged peak and tail current density.
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truncated α-subunit of Kv7.1 proteins, which miss the
pore region and imply a complete loss of function of the
α-subunit included in the tetramer, may present in our
patient-derived hiPSC-CMs at residual levels and serve as
poison peptides leading to defective channel assemble
with ancillary subunits and subsequently lead to the al-
tered kinetics.
Trafficking deficiency of the alpha subunit of Kv7.1
can, in some cases such as the KCNQ1-T587M, a known
trafficking mutation that caused haploinsufficiency, re-
duce localization of KCNH2 (HERG) to the cell mem-
brane [19]. This is due to a chaperone effect of KCNQ1-
WT that helps to enhance the membrane localization of
KCNH2. We measured the E4031 (a specific blocker of
the rapid activating delayed rectifier potassium channel
(IKr))-sensitive IKr density in hiPSC-CMs from the
LQT1 patient and control, and observed no difference
between them (data not shown). Moreover, in a latest re-
port involving modeling of Jervell and Lange-Nielsen
syndrome with patient hiPSC-CMs, the IKr tail density
recorded in the hiPSC-CMs bearing a c.1781G > A
KCNQ1 mutation with a partial KCNQ1 trafficking de-
fect was found comparable with the WT control [20].
The impact of KCNQ1 mutations on hERG might thus
be mutation specific.
Current drug therapy for LQTS including LQT1 is ham-
pered by a lack of specific and effective drugs that could
specifically target the affected ion channels. Beta-blockers
remain one of the few anti-arrhythmic drugs commonly
used in LQTS treatment, yet their effects are limited and
controversial. By high-throughput screening of the NIH
Molecular Libraries Small Molecule Repository collection
of over 300,000 compounds using an automated patch-
camp system, a small molecule ML277 has been identified
as a novel, potent and selective KV7.1 potassium channel
activator [16,21]. Closely resembling the findings from Yu
and colleagues [16], we demonstrated that ML277 in-
creased IKs by 1.3-fold to 1.64-fold and shortened APD
by ~20% in iCell as well as in LQT1 patient and family con-
trol hiPSC-CMs. The enhanced IKs in all cell groups is
most likely to be achieved via the WT (functional) KV7.1
channels. The effect of ML277 in enhancing the amplitude
of IKs as well as accelerating the activation rate (Figure 5)
was further validated in a recent report [22] in which
ML277 enhanced the IKs amplitude and shortened theAPD in the adult guinea pig and canine ventricular myo-
cytes. In the latter, ML277 also altered the gating kinetics
by negatively shifting the V(1/2). The effect of ML277 on
IKs activation is species specific [22]. It is believed that
ML277 inhibits the voltage-dependent inactivation kinetics
of KCNQ1 to contribute to the augmentation of current
amplitude while the hyperpolarizing shift of V(1/2) could
significantly increase the maximal conductance [16].
ML277 could become a potential new and targeted drug
for LQT1 without causing arrhythmia in normal individ-
uals. The action of ML277 depends on the unsaturated sta-
tus of the α-subunits of Kv7.1 channel with E1 subunits
[16]. The association of KCNE1 with KCNQ1may thus pre-
vent ML277 from triggering an arrhythmogenic effect in
healthy individuals. Given the rapid response of hiPSC-
CMs to ML277, we believe that the effects of ML277 are
most probably achieved via directly effects on the Kv7.1
channel rather than affecting the synthesis and/or the traf-
ficking of KV7.1. This notion is confirmed in a recent report
which indicated that ML277 activates IKs by binding to an
intersubunit space and allosterically influencing pore con-
ductance and gating transitions [23].
The inward rectifier potassium channel (IK1) current
plays an important role in determining the APD in car-
diomyocytes in addition to the L-type calcium current
(ICa,L), IKs and IKr. Absence of IK1 in hiPSC-CMs
leads to inactivation of the cardiac transient outward po-
tassium current (Ito) and loss of the phase 1 notch in an
AP [23], which could lead to more activated L-type cal-
cium channel and increased ICa,L [24] and prolonged
phase 2 repolarization. We noted that cardiomyocytes
derived from hiPSCs have a more depolarized status
than adult cardiomyocytes characterized by a lower rest-
ing membrane potential (~60 to −50 mV) and higher
automaticity (Figure 6). Such differences are associated
with lack of IK1 current, as highlighted by Bett and col-
leagues and by Clusin [25,26]. Although the impacts on
IKs and IKr currents and APD in hiPSC-CMs might be
relatively limited, lack of IK1 current could alter the car-
diac ion currents and APs and compromise the value of
hiPSC-CMs in disease modeling and drug testing. As car-
diac APs are shaped by several different outward currents
(IK1, ICa,L, IKs and IKr) with potential interactions or
interplay among them, it is not surprising to notice that
changes in IKs in hiPSC-CMs may not be proportional to
that of APD.
Ma et al. Stem Cell Research & Therapy  (2015) 6:39 Page 12 of 13In this study, we did not consider the impacts of lack of
IK1 current on the APs of hiPSC-CMs and we did not
evaluate the real-time contribution of cardiac ion currents
such as IKs and IKr on the APs in beating cardiomyocytes.
For precise disease modeling and more accurate drug test-
ing, it might be valuable, in future studies, to restore IK1
current in hiPSC-CMs to produce more physiological rele-
vant APs and to perform real-time measurement of cardiac
ion currents (such as ICa,L, IKs and IKr) concurrently with
cardiac APs. Technologies such as the dynamic AP clamp
[25,26] could be adopted to restore IK1 currents in hiPSC-
CMs. Moreover, the efficacy and safety of ML277 could be
tested in animal models.
Our data demonstrate that multiple factors can contrib-
ute to the pathology or act to correct LQTS. LQT1 patient
hiPSC-CMs show decreased IKs amplitude and altered
gaiting kinetics with the V(1/2) shifted in the hypopolariz-
ing direction. ML277, on the other hand, enhanced the
amplitude of IKs as well as restored the kinetic changes by
accelerating the activation rate. Following the example of
ML277, we believe that more candidate drugs targeting
multiple factors could be identified for the potential ther-
apy of LQT1.
Conclusions
From a LQT1 patient, we identified a novel heterozygous
exon 7 deletion mutation in the KCNQ1 gene that leads to
potential haploinsufficiency and trafficking defect. We
generated hiPSC-CMs which faithfully recapitulated the
typical LQT1 phenotypes. We found that the KV7.1 activa-
tor ML277 could partially rescue the electrophysiological
phenotypes of LQT1 and may have therapeutic potential.
Additional file
Additional file 1: A supplemental document describing supplemental
methods and results.
Abbreviations
AP: action potential; APD: action potential duration; ECG: electrocardiogram;
hiPSC-CM: human induced pluripotent stem cell cardiomyocyte;
hiPSC: human induced pluripotent stem cell; ICa,L: L-type calcium current;
IK1: inward rectifier potassium channel; IKr: rapid activating delayed rectifier
potassium channel; IKs: slowly activating delayed rectifier potassium channel;
KCNQ1: potassium channel, voltage-gated KQT-like subfamily Q, member 1;
LQTS: long QT syndrome; LQT1: type 1 long QT syndrome; V(1/2):
half-maximal activation voltage; WT: wild type.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
DM and LJL performed the hiPSC reprogramming and hiPSC-CM cardiac
differentiation. JL and ZL performed the patch-clamp assays. DH and OI
carried out RT-PCR, western blot and immunofluorescence assays. RL
contributed to conception, patient recruitment, clinical data acquisition and
genetic testing. WS contributed to conception and the patch-clamp assays.
SAC participated in analysis and interpretation of data, manuscript editing
and gave final approval of the version to be published. HW performed theexperimental design, study coordination, supervision and manuscript
drafting. All authors read and approved the final manuscript.
Acknowledgements
This work was supported by the National Medical Research Council (NMRC
EDG10may050), the National Research Foundation (NRF2008-CRP001-68), the
Duke-NUS GOH Cardiovascular Research Award (GCR/2012/0005R, GCR/2012/
0006, and GCR/2013/008), and the National Medical Research Council
(NMRC/STaR/011/2012) of Singapore. Written informed consent was obtained
from the patient/participant for publication of their individual details and
accompanying images in this manuscript. The consent form is held by the
authors/by the authors’ institution/in the patients’ clinical notes and is
available for review by the Editor-in-Chief.
Author details
1National Heart Research Institute Singapore, National Heart Centre
Singapore, 5th Hospital Drive, Singapore 169609, Singapore. 2Cardiovascular
& Metabolic Disorders Program, Duke-NUS Graduate Medical School
Singapore, 8 College Road, Singapore 169857, Singapore. 3National Heart
and Lung Institute, Imperial College, South Kensington Campus, London
SW7 2AZ, UK.
Received: 3 August 2014 Revised: 27 February 2015
Accepted: 27 February 2015
References
1. Itzhaki I, Maizels L, Huber I, Zwi-Dantsis L, Caspi O, Winterstern A, et al.
Modelling the long QT syndrome with induced pluripotent stem cells.
Nature. 2011;471:225–9.
2. Moretti A, Bellin M, Welling A, Jung CB, Lam JT, Bott-Flugel L, et al. Patient-specific
induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med.
2010;363:1397–409.
3. Yazawa M, Hsueh B, Jia X, Pasca AM, Bernstein JA, Hallmayer J, et al. Using
induced pluripotent stem cells to investigate cardiac phenotypes in
Timothy syndrome. Nature. 2011;471:230–4.
4. Ma D, Wei H, Zhao Y, Lu J, Li G, Sahib NB, et al. Modeling type 3 long QT
syndrome with cardiomyocytes derived from patient-specific induced pluripotent
stem cells. Int J Cardiol. 2013;168:5277–86.
5. Vincent GM. The molecular genetics of the long QT syndrome: genes
causing fainting and sudden death. Annu Rev Med. 1998;49:263–74.
6. Morita H, Wu J, Zipes DP. The QT syndromes: long and short. Lancet.
2008;372:750–63.
7. Roden DM. Clinical practice. Long-QT syndrome. N Engl J Med. 2008;358:169–76.
8. Splawski I, Shen J, Timothy KW, Lehmann MH, Priori S, Robinson JL, et al.
Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A,
KCNE1, and KCNE2. Circulation. 2000;102:1178–85.
9. Li H, Chen Q, Moss AJ, Robinson J, Goytia V, Perry JC, et al. New mutations
in the KVLQT1 potassium channel that cause long-QT syndrome.
Circulation. 1998;97:1264–9.
10. Murray A, Donger C, Fenske C, Spillman I, Richard P, Dong YB, et al. Splicing
mutations in KCNQ1: a mutation hot spot at codon 344 that produces in
frame transcripts. Circulation. 1999;100:1077–84.
11. Tsuji-Wakisaka K, Akao M, Ishii TM, Ashihara T, Makiyama T, Ohno S, et al.
Identification and functional characterization of KCNQ1 mutations around the
exon 7–intron 7 junction affecting the splicing process. Biochim Biophys Acta.
1812;2011:1452–9.
12. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al.
Induction of pluripotent stem cells from adult human fibroblasts by defined
factors. Cell. 2007;131:861–72.
13. Ma D, Wei H, Lu J, Ho S, Zhang G, Sun X, et al. Generation of patient-specific
induced pluripotent stem cell-derived cardiomyocytes as a cellular model of
arrhythmogenic right ventricular cardiomyopathy. Eur Heart J.
2013;34:1122–33.
14. Lian X, Hsiao C, Wilson G, Zhu K, Hazeltine LB, Azarin SM, et al. Robust
cardiomyocyte differentiation from human pluripotent stem cells via
temporal modulation of canonical Wnt signaling. Proc Natl Acad Sci U S A.
2012;109:E1848–57.
15. Ma J, Guo L, Fiene SJ, Anson BD, Thomson JA, Kamp TJ, et al. High purity
human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological
properties of action potentials and ionic currents. Am J Physiol Heart Circ Physiol.
2011;301:H2006–17.
Ma et al. Stem Cell Research & Therapy  (2015) 6:39 Page 13 of 1316. Yu H, Lin Z, Mattmann ME, Zou B, Terrenoire C, Zhang H, et al. Dynamic
subunit stoichiometry confers a progressive continuum of pharmacological
sensitivity by KCNQ potassium channels. Proc Natl Acad Sci U S A.
2013;110:8732–7.
17. Wei H, Tan G, Manasi, Qiu S, Kong G, Yong P, et al. One-step derivation of
cardiomyocytes and mesenchymal stem cells from human pluripotent stem
cells. Stem Cell Res. 2012;9:87–100.
18. Tsuji K, Akao M, Ishii TM, Ohno S, Makiyama T, Takenaka K, et al. Mechanistic
basis for the pathogenesis of long QT syndrome associated with a common
splicing mutation in KCNQ1 gene. J Mol Cell Cardiol. 2007;42:662–9.
19. Biliczki P, Girmatsion Z, Brandes RP, Harenkamp S, Pitard B, Charpentier F,
et al. Trafficking-deficient long QT syndrome mutation KCNQ1-T587M
confers severe clinical phenotype by impairment of KCNH2 membrane
localization: evidence for clinically significant IKr-IKsalpha-subunit interaction.
Heart Rhythm. 2009;6:1792–801.
20. Zhang M, D’Aniello C, Verkerk AO, Wrobel E, Frank S, Ward-van Oostwaard D,
et al. Recessive cardiac phenotypes in induced pluripotent stem cell models of
Jervell and Lange-Nielsen syndrome: Disease mechanisms and pharmaco-
logical rescue. Proc Natl Acad Sci U S A. 2014;111:E5383–92.
21. Mattmann ME, Yu H, Lin Z, Xu K, Huang X, Long S, et al. Identification of
(R)-N-(4-(4-methoxyphenyl)thiazol-2-yl)-1-tosylpiperidine-2-carboxamide,
ML277, as a novel, potent and selective K(v)7.1 (KCNQ1) potassium channel
activator. Bioorg Med Chem Lett. 2012;22:5936–41.
22. Xu Y, Wang Y, Zhang M, Jiang M, Rosenhouse-Dantsker A, Wassenaar T,
et al. Probing binding sites and mechanisms of action of an IKsActivator by
computations and experiments. Biophys J. 2015;108:62–75.
23. Cordeiro JM, Nesterenko VV, Sicouri S, Goodrow Jr RJ, Treat JA, Desai M,
et al. Identification and characterization of a transient outward K+ current in
human induced pluripotent stem cell-derived cardiomyocytes. J Mol Cell
Cardiol. 2013;60:36–46.
24. Wang Y, Cheng J, Tandan S, Jiang M, McCloskey DT, Hill JA. Transient-outward
K+ channel inhibition facilitates L-type Ca2+ current in heart. J Cardiovasc
Electrophysiol. 2006;17:298–304.
25. Bett GC, Kaplan AD, Lis A, Cimato TR, Tzanakakis ES, Zhou Q, et al. Electronic
‘expression’ of the inward rectifier in cardiocytes derived from human-induced
pluripotent stem cells. Heart Rhythm. 2013;10:1903–10.
26. Clusin WT. Restoring the resting potential brings maturity to induced stem
cell-derived human cardiac myocytes. Heart Rhythm. 2013;10:1911–2.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
